The Developing Regorafenib Eye drops for neovascular Age ‐related Macular degeneration (DREAM) study: an open‐label phase II trial

ConclusionsThe programme was terminated after phase IIa ended because efficacy was lower than with current nAMD treatments. According to elaboratepost hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye).

Source: British Journal of Clinical Pharmacology - November 25, 2018 Category: Drugs & Pharmacology Authors: Antonia M. Joussen, Sebastian Wolf, Peter K. Kaiser, David Boyer, Thomas Schmelter, Rupert Sandbrink, Oliver Zeitz, Gesa Deeg, Annett Richter, Torsten Zimmermann, Joachim Hoechel, Ulf Buetehorn, Walter Schmitt, Brigitte Stemper, Michael K. B Tags: ORIGINAL ARTICLE Source Type: research